logo
What Is Hyperglycemia and How Do You Manage It?

What Is Hyperglycemia and How Do You Manage It?

Health Line11-07-2025
Key takeaways
Hyperglycemia (high blood sugar) can develop over time and may not be immediately noticeable, but it can lead to serious health issues if not addressed. It may be caused by not getting the right dosage of insulin, eating more carbs than usual, illness, and infection, among others.
Symptoms may include excessive thirst, excessive urination, blurry vision, fatigue, and sores that won't heal. In severe cases, hyperglycemia may cause diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar syndrome (HHS).
Managing blood sugar levels through regular monitoring, managing diabetes, exercise, and a balanced diet are key to preventing and treating hyperglycemia.
Several factors can contribute to hyperglycemia, including dietary choices and a sedentary lifestyle. Chronic high blood sugar is a symptom of diabetes.
Regular blood glucose testing is crucial for people with diabetes. This is because many people don't feel the effects of hyperglycemia.
Symptoms of hyperglycemia
According to the Centers for Disease Control and Prevention (CDC), target blood glucose levels for people with diabetes are typically:
between 80 and 130 mg/dL before you've eaten
under 180 mg/dL 2 hours after the first bite of your meal
Blood sugar levels that are higher than that may indicate unmanaged or undiagnosed diabetes or a need to adjust your diabetes treatment.
You may not feel the effects of hyperglycemia until levels are very high for an extended period of time. If you experience symptoms of hyperglycemia, it's important that you check your blood glucose levels and connect with a doctor.
Hyperglycemia symptoms that may develop over several days or weeks include:
The longer the condition is left untreated, the more severe it may become. Long-term effects of hyperglycemia include:
eye disease
kidney disease
cardiovascular disease
neuropathy, or nerve damage
Medical emergencies
Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar syndrome (HHS) are two conditions caused by very high glucose levels. Contact a doctor straight away if you suspect you've developed DKA or HHS.
DKA generally occurs in people with type 1 diabetes and is less common with type 2 diabetes. However, not everyone with these blood glucose levels will have DKA.
In addition to the usual symptoms of hyperglycemia, a person with DKA may also have:
ketonuria, or a higher-than-usual amount of ketones in their urine
breath that smells fruity
gastrointestinal issues, such as nausea, vomiting, or pain
dry skin
confusion
People with HHS typically have a blood glucose level over 600 mg/dL. In addition to excessive thirst and urination, symptoms may include:
fever
dehydration
neurological symptoms, such as confusion or delirium
Hyperglycemia causes
A number of factors can contribute to hyperglycemia, including:
not getting the right dosage of insulin or other glucose-lowering medication
eating more carbohydrates than usual
being less physically active than usual
illness or infection
high levels of stress
physical trauma, such as an orthopedic injury
If you have diabetes, you may also experience regular episodes of high blood sugar between 3 a.m. and 8 a.m., before you have eaten anything. This is known as the Dawn phenomenon. You could also experience the Somogyi effect, which is where you take insulin before bed and wake up with high blood sugar.
Treatment for hyperglycemia
Several treatments are available for chronic high blood sugar.
Monitor your glucose levels
An important part of managing diabetes is checking your blood glucose levels often, such as before you eat, after you eat, or at bedtime.
Then, record that number in a notebook, blood glucose log, or blood glucose tracking app so you and your doctor can monitor your treatment plan.
Knowing when your blood glucose levels are getting out of your target range can help you get your blood glucose back on track before more significant complications arise.
Get moving
Exercise is one of the best and most effective ways to keep your blood glucose levels where they should be and lower them if they get too high.
If you're on medications that increase insulin, talk with your doctor to determine the best times to exercise. If you have complications such as nerve or eye damage, ask your doctor which exercises might suit you best.
The American Diabetes Association notes that if your blood glucose level is above 240 mg/dL, your doctor may want to check your urine for ketones.
Exercising when ketones are in your body may cause your blood glucose level to rise even higher. While it's rare for those with type 2 diabetes to experience this, if you have high blood glucose and ketones, you should avoid exercise.
Analyze your eating habits
Work with a dietitian or nutritionist to construct a nutritious, interesting selection of meals that can help you manage your carbohydrate intake and prevent higher blood glucose levels.
Diet plans you may want to explore include:
the keto diet, which is low carb and high fat
the Mediterranean diet
the Dietary Approaches to Stop Hypertension (DASH) diet
a vegetarian or vegan diet
Evaluate your treatment plan
Your doctor may reevaluate your diabetes treatment plan based on your personal health history and your experiences with hyperglycemia. They may change the amount, type, or timing of your medication.
Don't adjust your medications without first talking with your doctor or diabetes educator.
Preventing hyperglycemia
A few lifestyle changes may help prevent hyperglycemia. Try the tips below:
Test yourself regularly: Test and record your blood glucose levels on a regular basis each day. Share this information with your doctor at every appointment.
Manage your carb intake: Know how many carbohydrates you're getting with each meal and snack. Strive to stay within the range approved by your doctor or dietitian. Keep this information with the records of your blood glucose levels.
Be diabetes smart: Have an action plan for if and when your blood glucose reaches certain levels. Take your medication as prescribed, being consistent about the amount and timing of your meals and snacks.
Have alcohol in moderation: Although hypoglycemia is a more likely outcome, drinking large amounts of alcohol can eventually lead to high blood glucose levels. If you're having alcohol, choose a drink that's low in carbs and sugar.
Wear medical identification: Medical bracelets or necklaces can help alert emergency responders to your diabetes if there's a greater problem.
When to contact a doctor
Seek immediate medical attention if you experience symptoms of DKA or HHS, like:
shortness of breath
nausea or vomiting
fever
confusion
dry mouth
Contact a doctor if your blood glucose readings are consistently high, whether in a fasting state or after meals. Also, let your doctor know if their recommended lifestyle measures are not making a difference in your readings.
Make an appointment if you notice new or worsening issues with your vision or skin or if you suspect you have nerve damage or other health issues that relate to high blood sugar.
To prepare for your appointment:
Bring a record of your blood sugar readings, including when your readings were taken and whether they were taken with or without food.
Pay close attention to any instructions a medical professional gives you regarding blood work — you may need to fast.
Bring a list of your current medications and supplements, as well as a list of questions to ask your doctor.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Munchkin Revolutionizes Breastfeeding Support with Groundbreaking Innovation Backed by New Clinical Research
Munchkin Revolutionizes Breastfeeding Support with Groundbreaking Innovation Backed by New Clinical Research

Yahoo

time10 minutes ago

  • Yahoo

Munchkin Revolutionizes Breastfeeding Support with Groundbreaking Innovation Backed by New Clinical Research

Coinciding with National Breastfeeding Awareness Month, new U.S. clinical research study shows 87% of moms using Munchkin's Flow Nipple Shield+ maintained breastfeeding through 12 months, more than doubling national success rates LOS ANGELES, August 04, 2025--(BUSINESS WIRE)--Munchkin Inc. ("Munchkin"), the most loved baby lifestyle brand in the world, owned by WHY Brands Inc. ("WHY"), today announced in conjunction with National Breastfeeding Awareness Month and World Breastfeeding Week, the completion of new groundbreaking clinical research that supports how Munchkin's Flow Nipple Shield+ is changing lives, empowering breastfeeding journeys and helping moms achieve their nursing goals with unprecedented success. According to Munchkin's recently completed U.S. clinical research study* of approximately 300 moms, the Flow Nipple Shield+ achieved remarkable results and showcased a paradigm shift in breastfeeding support, including: 87% of mothers continued breastfeeding at 12 months – more than double the national U.S. average of 39.5%** 98% met or exceeded their breastfeeding goals 77% reported increased confidence in their feeding journey after the first month, which is a critical point in time for self-assurance "Flow Nipple Shield+ represents a significant breakthrough in maternal health technology," says Dr. Mona Amin, Board Certified Pediatrician and International Board-Certified Lactation Consultant. "By removing the guesswork and offering real-time reassurance, it's a powerful tool to build confidence and strengthen mothers' trust in their own abilities while delivering measurable impact on breastfeeding success rates. This innovation could help reshape national maternal health outcomes by making a meaningful difference for families wanting to continue their breastfeeding journey." What sets this innovation apart is its first-to-market visual confirmation technology. Flow Nipple Shield+ features a unique channel that allows parents to actually see milk transfer during feeding – addressing one of the most common anxieties new mothers face. Made with 100% food-grade silicone and packaged in a convenient travel-friendly steam sterilizer case, Flow Nipple Shield+ is designed to support better latch, confirm milk transfer and reduce postpartum stress. "We know that feeding doesn't look the same for everyone and that's okay," said Kristin Pagano, GM Infant Nutrition at Munchkin and mom of two. "The Flow Nipple Shield+ was created to offer compassionate, judgement-free support for parents navigating the ups and downs of feeding. This month, we're proud to make it even more accessible because every parent deserves the right to feel confident, capable and supported in how they nourish their baby." Beyond individual families, Munchkin is committed to making a broader impact. The company has donated more than $100,000 worth of Flow Nipple Shield+ units to WIC (Special Supplemental Nutrition Program for Women, Infants, and Children) chapters throughout the U.S. this year ensuring that underserved families across the country have access to this game-changing support. WIC is a division of the USDA's Food & Nutrition Services that provides breastfeeding support, touching more than 43% of births in the U.S. with its services. The Munchkin Flow Nipple Shield+ Starter Kits (shield, cleaning syringe, and travel case) retails for $39.99 at Walmart, Target and Amazon. This August, Munchkin is making it even more accessible by offering a FREE Flow Replacement Kit (brand-new nipple shield and a travel case that doubles as a steam sterilizer) with every Flow Nipple Shield+ purchase. To learn more about Munchkin and first account testimonials from moms using Flow, please visit or follow us on Facebook and Instagram. *Completed clinical trial of approximately 300 U.S. moms, Munchkin Inc. x Emmes, Evaluating the Efficacy and User Satisfaction of Flow, August 2023-July 2025.**According to data from the Centers for Disease Control and Prevention (CDC), the national U.S. average of mothers continuing to breastfeed at 12 months for infants born in 2021 was 39.5%. Source: HERE. About Munchkin Inc. For more than 30 years, Munchkin Inc., the baby lifestyle brand owned by WHY Brands Inc, has produced innovative products and functional gear for children and their caregivers. Munchkin has 350+ patents to date, and more than 250 international product and brand design awards. Munchkin products are sold in more than 50 countries and have received over 1.45 million five-star reviews. Munchkin has been awarded Great Place to Work for four consecutive years and is recognized as a 2024 Best Places to Work by Built In. Munchkin has been honored on Fast Company's annual "Brands That Matter" list for two consecutive years, including 2024, and ranked number eight on Fortune's list of "Most Innovative Companies" in 2023. As the only baby brand in the United Nations Global Compact, the company prioritizes corporate social responsibility with commitments to environmental protection and animal welfare, which are highlighted in its annual Sustainability Report. Learn more at and About WHY Brands Inc. WHY is a portfolio of brands that invent, develop, and design creative products across an array of categories. With every new idea and undertaking, we ask and end with WHY. That spirit of inquiry drives our commitment to innovation, highlighted by 350+ patents to date. We believe great ideas and next-generation design can be lifechanging. WHY's portfolio includes baby lifestyle brand Munchkin and Curio Home Goods. Learn more at View source version on Contacts Media Contact flowpr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Neutra Corp's Subsidiary, Neutra Life Sciences, Expands Rapidly With New Joint Venture Partnerships
Neutra Corp's Subsidiary, Neutra Life Sciences, Expands Rapidly With New Joint Venture Partnerships

Yahoo

time10 minutes ago

  • Yahoo

Neutra Corp's Subsidiary, Neutra Life Sciences, Expands Rapidly With New Joint Venture Partnerships

HOUSTON, TX - August 4, 2025 (NEWMEDIAWIRE) - Neutra Corp (OTC: NTRR) is hitting its stride with the purposeful growth in the clinical research industry with Neutra Life Sciences. Since the successful launch of its Site Management Organization (SMO), Neutra Life Sciences has strategically positioned itself for significant growth in the latter part of 2025 and the beginning of 2026. Neutra Life Sciences has solidified its multi-specialty platform by securing another suite of Joint Venture Partnerships. These new joint venture sites will be in the onboarding process: Podiatry Epic Foot & Ankle Centers ( Radiation Oncology Aspire Hospital Cancer Centers ( Dermatology Radiant Dermatology & Aesthetics Clinic ( Expanding into more specialties gives Neutra Life Sciences a significant advantage over other organizations in the space. This diversification in medical specialties allows NLS to serve a broader patient population and meet increasing demands in clinical research. Looking ahead, Neutra Life Sciences plans to continue expanding into additional specialties, further enhancing its ability to support Contract Research Organizations (CROs) and Sponsors with a wider array of clinical indications. This strategic growth enables the company to play a critical role in accelerating the development of innovative treatments across a broader spectrum of therapeutic areas. "Our growth reflects the increasing demand for high-quality, integrated clinical research solutions," said Sydney Jim, President and CEO of Neutra Corp. "By aligning with established private practices and opening these new specialized sites, we are not only expanding our service offerings but also fostering innovation in patient care and research." Neutra Life Sciences remains focused on building a robust network of clinical research sites, delivering exceptional services to its partners, and advancing its mission to improve health outcomes through cutting-edge collaboration. For more information about the role of clinical research sites in advancing medicine, or to learn how to participate in a clinical trial, please contact Neutra Life Sciences via phone 281-598-0200 or email at info@ Neutra has made the strategic decision to divest its subsidiary, VIVIS Corporation, a hemp-based cannabis entity, as part of a broader shift toward long-term growth in the life sciences sector. This transition reflects the company's renewed focus on advancing its clinical research capabilities through its newly launched site management organization (SMO). By reallocating resources and leadership attention to the SMO business, Neutra aims to support high-quality clinical trials and expand its presence in the evolving healthcare and biotechnology landscape. This move underscores the company's commitment to innovation and delivering value in areas with greater regulatory stability and long-term market potential. About Neutra Corp Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being. Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options. Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone's past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof. View the original release on Sign in to access your portfolio

Hims & Hers Q2 2025: What You Need to Know Ahead of Earnings
Hims & Hers Q2 2025: What You Need to Know Ahead of Earnings

Yahoo

time10 minutes ago

  • Yahoo

Hims & Hers Q2 2025: What You Need to Know Ahead of Earnings

Hims & Hers Health (NYSE:HIMS) reports Q2 2025 earnings after U.S. markets close on Monday, August 4. Analysts expect revenue of around $552 million, up 75% YoY, and adjusted EPS near $0.15, roughly up 15% YoY. Despite the volatility, shares are up 154% YTD, pushing the forward P/E to roughly 57. Subscriber growth remains the core engine investors care about. Subscribers increased 38% in Q1, reaching 2.4 million. Weight-loss GLP-1 offerings are a swing factor, but Novo Nordisk (NYSE:NVO) ended its partnership on 23 Jun 2025, citing illegal mass compounding and deceptive marketing, which sent Hims down 30%. Analysts estimate that up to half of Hims' projected weight-loss revenue could be at risk. Investors need clarity on FDA scrutiny, formulary access, and whether compounded semaglutide margins can hold. Marketing spend, revenue per average user, and progress on the ZAVA integration will also be closely watched. Management guides FY25 revenue of $2.32.4 billion and low-teens EBITDA margins. Any uplift to those guides or clean regulatory commentary could keep momentum intact. But with valuation stretched, even a top-line beat may disappoint if churn ticks up or compliance costs bite. Q2 will test whether the telehealth disrupter can scale responsibly before regulators step in. This article first appeared on GuruFocus. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store